Loading...
Recent updates on CAR T clinical trials for multiple myeloma
Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturati...
Na minha lista:
| Udgivet i: | Mol Cancer |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6829852/ https://ncbi.nlm.nih.gov/pubmed/31684964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-019-1092-1 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|